Mirum Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	471.79	336.89	186.37	77.06	19.14	-
Revenue Growth (YoY)	53.66%	80.76%	141.85%	302.67%	-	-
Cost of Revenue	94.76	81.64	47.04	12.37	1.9	-
Gross Profit	377.04	255.25	139.34	64.69	17.24	-
Selling, General & Admin	239.73	202.22	145.88	89.07	59.22	22.69
Research & Development	179.1	140.63	102.61	106.84	131.43	81.61
Operating Expenses	418.83	342.85	248.49	195.91	190.65	104.3
Operating Income	-41.79	-87.61	-109.15	-131.22	-173.41	-104.3
Interest Expense	-14.37	-14.31	-15.11	-15.98	-17.59	-0.34
Interest & Investment Income	12.51	13.79	13.74	3.86	0.37	1.56
Currency Exchange Gain (Loss)	1	1.2	1.8	-	-	-
Other Non Operating Income (Expenses)	1.82	0.01	-4.62	1.27	106.69	-0.19
EBT Excluding Unusual Items	-40.83	-86.91	-113.35	-142.07	-83.95	-103.26
Other Unusual Items	-	-	-49.08	-	-	-
Pretax Income	-40.83	-86.91	-162.42	-142.07	-83.95	-103.26
Income Tax Expense	0.59	1.03	0.99	-6.41	0.04	0.01
Net Income	-41.42	-87.94	-163.42	-135.67	-83.99	-103.27
Net Income to Common	-41.42	-87.94	-163.42	-135.67	-83.99	-103.27
Shares Outstanding (Basic)	49	48	41	34	30	25
Shares Outstanding (Diluted)	49	48	41	34	30	25
Shares Change (YoY)	4.69%	16.23%	20.31%	12.07%	20.08%	119.84%
EPS (Basic)	-0.84	-1.85	-4.00	-4.01	-2.77	-4.09
EPS (Diluted)	-0.84	-1.85	-4.00	-4.02	-2.77	-4.09
Free Cash Flow	44.32	9.33	-71.05	-120.41	-132.78	-89.3
Free Cash Flow Per Share	0.90	0.20	-1.74	-3.54	-4.38	-3.54
Gross Margin	79.92%	75.77%	74.76%	83.94%	90.06%	-
Operating Margin	-8.86%	-26.00%	-58.57%	-170.28%	-906.12%	-
Profit Margin	-8.78%	-26.10%	-87.68%	-176.05%	-438.86%	-
Free Cash Flow Margin	9.39%	2.77%	-38.12%	-156.26%	-693.81%	-
EBITDA	-17.57	-63.98	-98.33	-127.98	-172.82	-103.99
EBITDA Margin	-3.72%	-18.99%	-52.76%	-166.08%	-	-
D&A For EBITDA	24.23	23.63	10.83	3.24	0.6	0.31
EBIT	-41.79	-87.61	-109.15	-131.22	-173.41	-104.3
EBIT Margin	-8.86%	-26.00%	-58.57%	-170.28%	-	-
Revenue as Reported	471.79	336.89	186.37	77.06	19.14	-
Advertising Expenses	-	11.5	6.3	4	9.2	-

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q